NASDAQ · ELUTHealthcareBiotechnology

Elutia financials

$0.7890−2.59%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
Revenue$12.3M$14.5M$24.7M
Gross profit$6.6M$6.7M$11.1M
Gross margin53.7%46.4%44.7%
Operating income-$26.9M-$30.7M-$30.5M
Net income$53.4M-$53.9M-$37.7M
Net margin434.2%−372.9%−152.2%
Diluted EPS$0.87$-1.86$-2.07
EBITDA-$15.6M-$15.9M-$26.8M
Operating cash flow-$44.8M-$22.7M-$21.8M
Free cash flow-$46.7M-$23.3M-$22.1M
Diluted shares45.9M29.1M18.2M

Balance sheet

Period endDec 31Dec 31Dec 31
Cash & equivalents$36.4M$13.2M$19.3M
Short-term investments$0.00$0.00$0.00
Total debt$0.00$23.9M$23.7M
Total assets$62.4M$36.1M$43.4M
Total liabilities$34.7M$82.4M$69.3M
Shareholders' equity$27.7M-$46.3M-$25.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology